Metabolomics Workbench : NIH Data Repository

Return to study ST001929 main page

MB Sample ID: SA178512

Local Sample ID:	180731bJWsa10_2
Subject ID:	SU002007
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Gender:	Female

Select appropriate tab below to view additional metadata details:

All
Subject
Factors
Collection
Treatment
Sample Preparation
Chromatography
Analysis
MS

Treatment:

Treatment ID:	TR002019
Treatment Summary:	As part of the parent study, daidzein, equol, and ODMA concentrations were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) as detailed elsewhere (Franke et al 2009). These previously measured concentrations were used to classify metabotypes. Each urine sample was identified as being ODMA producer/non-producer and equol producer/non-producer based on a cut-off of equol/ODMA:daidzein ratio of 0.018 (36). All samples, except two samples, which were excluded from selection, had daidzein concentrations >2 nmol/mg creatinine, indicating sufficient presence of the precursor metabolite for metabolite detection.

Treatment ID:

TR002019

Treatment Summary:

As part of the parent study, daidzein, equol, and ODMA concentrations were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) as detailed elsewhere (Franke et al 2009). These previously measured concentrations were used to classify metabotypes. Each urine sample was identified as being ODMA producer/non-producer and equol producer/non-producer based on a cut-off of equol/ODMA:daidzein ratio of 0.018 (36). All samples, except two samples, which were excluded from selection, had daidzein concentrations >2 nmol/mg creatinine, indicating sufficient presence of the precursor metabolite for metabolite detection.